Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03685331
Recruitment Status : Recruiting
First Posted : September 26, 2018
Last Update Posted : March 1, 2021
Sponsor:
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

Brief Summary:
The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive breast cancer and BRCA1 or BRCA2 mutations.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Locally Advanced Breast Cancer Advanced Breast Cancer BRCA2 Mutation BRCA1 Mutation Drug: Palbociclib Drug: Olaparib Drug: Fulvestrant Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 54 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: The phase I component is a dose-escalation study. Dose escalation will follow a 3+3 design. An additional cohort of at least 36 patients (total number of patients in phase I and phase II = 54) will be included on the single-arm, non-randomized phase II portion of this clinical trial.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Harnessing Olaparib, Palbociclib and Endocrine Therapy: A Phase I/II Trial of Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (HOPE)
Actual Study Start Date : October 15, 2020
Estimated Primary Completion Date : April 2024
Estimated Study Completion Date : April 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Phase I Level 0

(28-day cycle)

Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 75 mg by mouth daily, days 1-21, beginning at cycle 1

Drug: Palbociclib
Combination of palbociclib, olaparib, and fulvestrant.

Drug: Olaparib
Combination of palbociclib, olaparib, and fulvestrant.

Drug: Fulvestrant
Combination of palbociclib, olaparib, and fulvestrant.

Experimental: Phase I Level 1

(28-day cycle)

Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 100 mg by mouth daily, days 1-21, beginning at cycle 1

Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal.

Drug: Palbociclib
Combination of palbociclib, olaparib, and fulvestrant.

Drug: Olaparib
Combination of palbociclib, olaparib, and fulvestrant.

Drug: Fulvestrant
Combination of palbociclib, olaparib, and fulvestrant.

Experimental: Phase I Level 2

(28-day cycle)

Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly, Day 1 + 500 mg intramuscularly Cycle 0 Day 15; palbociclib 125 mg by mouth daily, days 1-21, beginning at cycle 1

Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal.

Drug: Palbociclib
Combination of palbociclib, olaparib, and fulvestrant.

Drug: Olaparib
Combination of palbociclib, olaparib, and fulvestrant.

Drug: Fulvestrant
Combination of palbociclib, olaparib, and fulvestrant.

Experimental: Phase II

(28-day cycle) Olaparib 300 mg by mouth twice a day, days 1-28; fulvestrant 500 mg intramuscularly once monthly on Day 1 of each cycle + 500 mg intramuscularly on Cycle 1 Day 15; palbociclib dose as per maximum tolerated dose determined during Phase I, by mouth daily, days 1-21

Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other protocol-mandated study removal.

Drug: Palbociclib
Combination of palbociclib, olaparib, and fulvestrant.

Drug: Olaparib
Combination of palbociclib, olaparib, and fulvestrant.

Drug: Fulvestrant
Combination of palbociclib, olaparib, and fulvestrant.




Primary Outcome Measures :
  1. Progression-free survival [ Time Frame: From first dose of protocol therapy to progression or death due to any cause, whichever comes first, an estimated average of 7 months ]

Secondary Outcome Measures :
  1. Objective response rate [ Time Frame: From first dose of protocol therapy to progression or death due to any cause, whichever comes first, an estimated average of 7 months ]
    Includes complete and partial response as per RECIST 1.1 criteria. Overall response rate will be defined as the proportion of patients within the efficacy analysis set that experience a complete or partial response.

  2. 24-week clinical benefit rate [ Time Frame: From the date of study treatment until the date of progression, an estimated average of 7 months ]
    Defined as the proportion of patients within the efficacy analysis set that experience clinical benefit ≥24 weeks.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Females/males ≥ age 18
  • Germline or somatic deleterious or suspected deleterious mutation in BRCA1 or BRCA2
  • Metastatic or locally advanced unresectable breast cancer that is ER and/or PR positive (>1%) and HER2 nonamplified
  • Prior treatment with 0-2 prior lines of chemotherapy for metastatic breast cancer
  • Regarding prior platinum-based chemotherapy:

    1. Patients who received prior platinum-based chemotherapy in the adjuvant or neoadjuvant setting for breast cancer are eligible if treatment was completed at least 12 months prior to diagnosis of metastatic disease.
    2. Patients who received platinum for advanced breast cancer are eligible to enter the study provided there was no evidence of disease progression during the platinum chemotherapy.
    3. Patients who received prior platinum-based as a potentially curative treatment for a prior non-breast cancer (e.g., ovarian cancer) with no evidence of disease for 5 years or greater prior to study entry are permitted.
  • Deemed a candidate for endocrine therapy (any prior endocrine therapy is permitted; no prior endocrine therapy is also permitted)
  • Adequate organ and bone marrow function
  • ECOG performance status 0-1
  • At least one measurable disease or disease that can be assessed by CT or MRI
  • Life expectancy ≥ 16 weeks
  • Postmenopausal as defined below. Women who are on pharmacologic ovarian suppression must have two negative urine or serum pregnancy tests: one during screening (within 28 days prior to study treatment) and one within 7 days prior to commencing treatment.

Postmenopausal is defined as one of the below:

  • Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments
  • Follicle stimulating hormone (FSH) levels in the post-menopausal range for women under 50
  • radiation-induced oophorectomy with last menses >1 year ago
  • chemotherapy-induced menopause with >1 year interval since last menses
  • bilateral oophorectomy or hysterectomy
  • on luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards as pharmacologic ovarian suppression
  • Female patients of childbearing potential (not post-menopausal as defined above) must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 1 month after last dose of study drug(s) to prevent pregnancy.
  • Male patients and their sexual partners of childbearing potential must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner.
  • Willing to comply with study requirements and procedures including use of appropriate contraception, willingness to discontinue herbal preparations / medications, and study biopsy if archival tissue is not available

Exclusion Criteria:

  • Involvement in study planning or conduct
  • Regarding prior olaparib or palbociclib,

    a) Phase II: Patients who previously progressed on olaparib or palbociclib for metastatic breast cancer treatment are excluded

  • Participation in another clinical study with an investigational product during the last 3 weeks
  • Systemic chemotherapy or radiotherapy (except palliative) within 3 weeks of start of study treatment
  • Major surgery within 2 weeks of start of study treatment
  • Other malignancy within the last 5 years with exceptions listed in the protocol
  • Concomitant strong or moderate CYP3A inhibitors/ inducers
  • Persistent toxicity of prior cancer therapy that is grade ≥ 2 except for alopecia or neuropathy
  • MDS or features suggestive of MDS/AML
  • Symptomatic uncontrolled brain metastases
  • Patients considered to be at poor medical risk
  • QTc >470 msec on 2 or more time points or a family history of long QT syndrome
  • Unable to swallow or absorb oral medication
  • Immunocompromised patients
  • Pregnant or breast-feeding
  • Hypersensitivity to olaparib, palbociclib, fulvestrant, or any excipients of these products
  • Known active hepatitis
  • Prior bone marrow transplant
  • Whole blood transfusions 120 days prior to signing consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03685331


Contacts
Layout table for location contacts
Contact: Payal Shah, MD 855-216-0098 PennCancerTrials@emergingmed.com

Locations
Layout table for location information
United States, Pennsylvania
Abramson Cancer Center of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Payal Shah, MD    855-216-0098    PennCancerTrials@emergingmed.com   
Sponsors and Collaborators
Abramson Cancer Center of the University of Pennsylvania
Investigators
Layout table for investigator information
Principal Investigator: Payal Shah, MD Abramson Cancer Center of the University of Pennsylvania
Layout table for additonal information
Responsible Party: Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier: NCT03685331    
Other Study ID Numbers: UPCC 21118
First Posted: September 26, 2018    Key Record Dates
Last Update Posted: March 1, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Abramson Cancer Center of the University of Pennsylvania:
HER2-negative
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Olaparib
Fulvestrant
Palbociclib
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Protein Kinase Inhibitors